search
Back to results

Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life (Ex Stress II)

Primary Purpose

Life Stress, Fatigue, Pain

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Extramel 10 mg - 140 UI SOD
Placebo - Excipient only
Sponsored by
Bionov
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Life Stress focused on measuring Super-Oxyd-Dismutase, SOD, melon juce, perceived stress

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the inclusion visit for the women of reproductive age.
  • Older than 30 years and younger than 65 years
  • BMI ≤ 30
  • Score greater than 30 on the Cohen perceived stress scale PSS 14.
  • Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits).
  • Presenting an impact of stress on at least one of the following domains.

    • pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale,
    • physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale,
    • the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test.
  • Stable professional activity since at least 1 year.
  • Completely healthy on the day of inclusion, and not taking any medicinal product or dietary supplement with an anti-stress or anti-pain objective.
  • Not taking any herbal tea or drink with an anti-stress or anti-pain objective.
  • Accepting not to modify his/her dietary habits.
  • Having given his/her free, informed and express consent.
  • Capable of understanding the nature of the objectives, the consequences of the study and accepting to comply with the protocol requirements.
  • Affiliated with a social security insurance or beneficiary of such an insurance system.

Exclusion Criteria:

  • Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician.
  • Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment.
  • Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment.
  • Pregnant and/or breast-feeding women.
  • Any person who does not satisfy by definition the inclusion criteria.
  • Adult protected by the law.
  • Any history of psychiatric disease.
  • Any pathology in progress or active in the previous month.
  • Any administration of a dietary supplement in progress or in the previous month.
  • Any subject who within the 3 months following inclusion is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Extramel 10 mg - 140 UI SOD

    Placebo - exipients only

    Arm Description

    This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.

    This arm receives daily one capsule Placebo containing excipients only.

    Outcomes

    Primary Outcome Measures

    Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3
    Evaluation performed by Cohen PSS 14 scale. It should be noted that in order to be included the patient had to present a minimum score of 30 on the Cohen scale.

    Secondary Outcome Measures

    Evaluation of evolution of Physical fatigue
    Evaluation performed by Prevost subjective fatigue scale and Ruffier test.
    Evaluation of evolution of Intellectual fatigue
    Evaluation performed by Stroop test, Reverse Stroop test and 15-words Rey test.
    Evaluation of evolution of pain
    Evaluation of subjects' perceived chronic pain (if existing), was performed using a simple visual analog scale (VAS).
    Evaluation of evolution of subject Quality of life
    Evaluation of subjects' quality of life, was performed by using Quality of Life SF36 scale.
    Evaluation of evolution of subject Quality of life
    Evaluation of subjects' quality of life, was performed by using Hamilton anxiety scale.
    Evaluation of evolution of subject Quality of life
    Evaluation of subjects' quality of life, was performed by using Personnal stress profile questionnary.

    Full Information

    First Posted
    January 11, 2013
    Last Updated
    January 17, 2013
    Sponsor
    Bionov
    Collaborators
    Seppic
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01767922
    Brief Title
    Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life
    Acronym
    Ex Stress II
    Official Title
    Multicentre, Double-blind Study Versus Placebo on the Impact and Safety of the Daily Administration of Extramel® 140 IU for 12 Weeks on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception, if Present, and the Impact on the Quality of Life of 70 Subjects Included, of Which 60 That Can be Evaluated
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2008 (undefined)
    Primary Completion Date
    May 2009 (Actual)
    Study Completion Date
    September 2009 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Bionov
    Collaborators
    Seppic

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Objectives of this Multicentre, double-blind study versus placebo were to evaluate impact and safety of the daily administration of Extramel® 140 IU SOD for 12 weeks on perceived stress, physical and intellectual fatigue, pain perception, if present, and the impact on the quality of life of 70 subjects included with 60 that can be evaluated.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Life Stress, Fatigue, Pain, Quality of Life
    Keywords
    Super-Oxyd-Dismutase, SOD, melon juce, perceived stress

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    61 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Extramel 10 mg - 140 UI SOD
    Arm Type
    Experimental
    Arm Description
    This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
    Arm Title
    Placebo - exipients only
    Arm Type
    Placebo Comparator
    Arm Description
    This arm receives daily one capsule Placebo containing excipients only.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Extramel 10 mg - 140 UI SOD
    Intervention Description
    Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks. Each volunteer was seen for the 3 visits: visit V1, so-called inclusion visit (D0), visit V2 at 28 days, tolerance of +/- 3 days, (D28) and visit V3 at 84 days, tolerance of +/- 3 days, (D84).
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo - Excipient only
    Primary Outcome Measure Information:
    Title
    Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3
    Description
    Evaluation performed by Cohen PSS 14 scale. It should be noted that in order to be included the patient had to present a minimum score of 30 on the Cohen scale.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Secondary Outcome Measure Information:
    Title
    Evaluation of evolution of Physical fatigue
    Description
    Evaluation performed by Prevost subjective fatigue scale and Ruffier test.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Title
    Evaluation of evolution of Intellectual fatigue
    Description
    Evaluation performed by Stroop test, Reverse Stroop test and 15-words Rey test.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Title
    Evaluation of evolution of pain
    Description
    Evaluation of subjects' perceived chronic pain (if existing), was performed using a simple visual analog scale (VAS).
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Title
    Evaluation of evolution of subject Quality of life
    Description
    Evaluation of subjects' quality of life, was performed by using Quality of Life SF36 scale.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Title
    Evaluation of evolution of subject Quality of life
    Description
    Evaluation of subjects' quality of life, was performed by using Hamilton anxiety scale.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Title
    Evaluation of evolution of subject Quality of life
    Description
    Evaluation of subjects' quality of life, was performed by using Personnal stress profile questionnary.
    Time Frame
    Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
    Other Pre-specified Outcome Measures:
    Title
    Evaluation of safety
    Description
    Assessment of the safety performed by analysis of adverse events that occurred throughout the study.
    Time Frame
    Global safty evaluation performed at the end of study.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the inclusion visit for the women of reproductive age. Older than 30 years and younger than 65 years BMI ≤ 30 Score greater than 30 on the Cohen perceived stress scale PSS 14. Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits). Presenting an impact of stress on at least one of the following domains. pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale, physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale, the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test. Stable professional activity since at least 1 year. Completely healthy on the day of inclusion, and not taking any medicinal product or dietary supplement with an anti-stress or anti-pain objective. Not taking any herbal tea or drink with an anti-stress or anti-pain objective. Accepting not to modify his/her dietary habits. Having given his/her free, informed and express consent. Capable of understanding the nature of the objectives, the consequences of the study and accepting to comply with the protocol requirements. Affiliated with a social security insurance or beneficiary of such an insurance system. Exclusion Criteria: Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician. Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment. Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment. Pregnant and/or breast-feeding women. Any person who does not satisfy by definition the inclusion criteria. Adult protected by the law. Any history of psychiatric disease. Any pathology in progress or active in the previous month. Any administration of a dietary supplement in progress or in the previous month. Any subject who within the 3 months following inclusion is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Thierry CANTIN, MD
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Patrick LEPRINCE, MD
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Hubert TAUPE, PharmD
    Organizational Affiliation
    ISOCLIN
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    24949549
    Citation
    Carillon J, Notin C, Schmitt K, Simoneau G, Lacan D. Dietary supplementation with a superoxide dismutase-melon concentrate reduces stress, physical and mental fatigue in healthy people: a randomised, double-blind, placebo-controlled trial. Nutrients. 2014 Jun 19;6(6):2348-59. doi: 10.3390/nu6062348.
    Results Reference
    derived

    Learn more about this trial

    Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life

    We'll reach out to this number within 24 hrs